Showing results (61-70 of 72) with videos related to

Sort By:
Pageof 8
Vaccine|December 10, 2015
Risk and outcomes of invasive pneumococcal disease in adults with underlying conditions in the post-PCV7 era, The NetherlandsGertjan H J Wagenvoort, Mirjam J Knol, Hester E de Melker, et al.
Infectious Diseases and Therapy|February 26, 2020
Estimating the Impact of Switching from a Lower to Higher Valent Pneumococcal Conjugate Vaccine in Colombia, Finland, and The Netherlands: A Cost-Effectiveness AnalysisSarah Pugh, Matt Wasserman, Margaret Moffatt, et al.
International Journal of STD & AIDS|October 1, 2008
Cost-effectiveness estimates for antenatal HIV testing in the NetherlandsM H Rozenbaum, G Verweel, D K F Folkerts, et al.
ESC Heart Failure|April 2, 2022
Healthcare resource use of patients with transthyretin amyloid cardiomyopathyRosa Lauppe, Johan Liseth Hansen, Anna Fornwall, et al.
ESC Heart Failure|May 13, 2022
Prevalence, characteristics, and mortality of patients with transthyretin amyloid cardiomyopathy in the Nordic countriesRosa Lauppe, Johan Liseth Hansen, Anna Fornwall, et al.
Infectious Diseases and Therapy|March 16, 2024
Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine Among US Children with Underlying Medical ConditionsMark H Rozenbaum, Erica Chilson, Raymond Farkouh, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 16, 2012
On discounting of health gains from human papillomavirus vaccination: effects of different approachesTjalke A Westra, Mehraj Parouty, Werner B Brouwer, et al.
Vaccine|January 8, 2024
Cost-effectiveness of 20-valent pneumococcal conjugate vaccine in US infantsMark H Rozenbaum, Liping Huang, Johnna Perdrizet, et al.
Vaccine|December 17, 2008
Excess drug prescriptions during influenza and RSV seasons in the Netherlands: potential implications for extended influenza vaccinationM D M Assink, J P Kiewiet, M H Rozenbaum, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|March 16, 2021
Estimating the annual economic burden for the management of patients with transthyretin amyloid polyneuropathy in SpainLucia Galan, Juan Gonzalez-Moreno, José Manuel Martínez-Sesmero, et al.
Pageof 8